Chronic knee and hip pain is a major cause of impaired mobility, physical and mental function and wellbeing. There is very strong evidence that informing people about their condition and how it can be manged, and controlled exercise/physical activity reduces joint pain and improves physical and mental health and wellbeing. Enabling Selfmanagement and Coping with Arthritis Pain through Exercise, ESCAPE-pain, (www.escape-pain.org) is a rehabilitation programme that integrates information and advice with a challenging, individualised, progressive exercise regimen.Evidence from clinical trials show ESCAPE-pain can reduce pain, improve mobility and physical and mental wellbeing for up to 2½ years. Participation alters participant's health beliefs and behaviours (increasing physical activity), as they come to appreciate how increasing physical activity is a selfmanagement strategy they can use to reduce and control their symptoms and alter the course of the condition. To encourage adoption of the programme we worked closely with clinical departments to set up and run ESCAPE-pain, and then sustain the programme. We created support materials, processes, toolkits etc. By the start of 2018 it was being delivered in > 50 clinical departments across the UK. Unfortunately, constraints within the NHS severely limits the number of people who have access to the programme. Therefore we have also looked at alternatives ways of delivering the programme. This presentation will describe: the processes, barriers and facilitators to implementation that we encountered; how these were surmounted, where possible and worked with/around where it wasn't; and our plans for large scale roll-out, evolution and enhancements to ESCAPE-pain. Disclosures: The author has declared no conflicts of interest. In terms of current pharmacological therapies for osteoarthritis (OA), we have recently seen a number of meta-analyses suggesting that paracetamol has very little benefit for OA pain; NSAIDs demonstrate reasonable benefits in such analyses, with significant side effects; and American data has highlighted many more problems with opioids than previously thought. Happily a number of new pharmacological therapies are on the way and some of these in advanced trial phase will be reviewed. Most have been trialled in knee OA. In terms of analgesics, a novel microsphere-based delivery system has enabled the development of a triamcinolone acetonide-extended release formulation for intra-articular (IA) delivery, providing sustained IA presence. Phase II and III trials of this agent have demonstrated benefits over placebo through 12 weeks post-injection, with studies in diabetic OA patients demonstrating no glucose flares. This product is now licensed in the USA. Results from an anti-interleukin1 alpha/beta dual variable domain immunoglobulin (ABT-981) were however disappointing, with limited effects on pain and no benefits on MRIassessed synovitis. The efficacy of anti-nerve growth factor (NGF) therapies has long been established, though side effects such as rapidly progressive OA have delayed development. However a number of these anti-NGFs are currently back in large phIII trials. These therapies have happily created more interest in the NGF nociceptive pathway, and recently a phII study demonstrated analgesic benefits above placebo through 12 weeks following IA injection of synthetic trans-capsaicin which targets the transient receptor potential vanilloid 1 (capsaicin receptor) resulting in desensitisation of nociceptive neurones. Structure modification of OA remains a difficult challenge, but putative pharmacological DMOADs are also showing promise, though perhaps not surprisingly on structural endpoints more than symptoms. There has been a trend for some of these therapies to be delivered IA for maximal local effect. Sprifermin is a recombinant human fibroblast growth factor 18 given IA that promotes chondrocyte growth, and recent two year results from a phase II RCT suggest reduction in cartilage loss with the active therapy, though no benefits above placebo for pain. Phase II data from an RCT of a small molecule Wnt signalling pathway inhibitor (SM04690) given IA has also been reported, with sub-analyses reporting benefits on symptoms and X-ray joint space width. There has recently been increased understanding of the performance metrics of Xray and MRI, with modern supervised machine learning techniques enabling sensitive assessment of OA progression with reduced patient numbers. In a six month phase II dose-ranging study of a novel oral cathepsin-K inhibitor (MIV-711), although the primary pain outcome was not achieved, significant reduction in MRI bone shape change (the most sensitive measure of OA progression and a predictor of joint replacement) was demonstrated with both doses of active agent. Disclosures: P.C. consultancies; Abbvie, BMS, Centrexion, Flexion, GSK, Medivir, Novartis, Pfizer. Member of speakers' bureau; Abbvie, BMS, Samumed.
I078 UPDATE ON PHARMACOLOGICAL THERAPIES FOR OSTEOARTHRITIS
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In terms of current pharmacological therapies for osteoarthritis (OA), we have recently seen a number of meta-analyses suggesting that paracetamol has very little benefit for OA pain; NSAIDs demonstrate reasonable benefits in such analyses, with significant side effects; and American data has highlighted many more problems with opioids than previously thought. Happily a number of new pharmacological therapies are on the way and some of these in advanced trial phase will be reviewed. Most have been trialled in knee OA. In terms of analgesics, a novel microsphere-based delivery system has enabled the development of a triamcinolone acetonide-extended release formulation for intra-articular (IA) delivery, providing sustained IA presence. Phase II and III trials of this agent have demonstrated benefits over placebo through 12 weeks post-injection, with studies in diabetic OA patients demonstrating no glucose flares. This product is now licensed in the USA. Results from an anti-interleukin1 alpha/beta dual variable domain immunoglobulin (ABT-981) were however disappointing, with limited effects on pain and no benefits on MRIassessed synovitis. The efficacy of anti-nerve growth factor (NGF) therapies has long been established, though side effects such as rapidly progressive OA have delayed development. However a number of these anti-NGFs are currently back in large phIII trials. These therapies have happily created more interest in the NGF nociceptive pathway, and recently a phII study demonstrated analgesic benefits above placebo through 12 weeks following IA injection of synthetic trans-capsaicin which targets the transient receptor potential vanilloid 1 (capsaicin receptor) resulting in desensitisation of nociceptive neurones. Structure modification of OA remains a difficult challenge, but putative pharmacological DMOADs are also showing promise, though perhaps not surprisingly on structural endpoints more than symptoms. There has been a trend for some of these therapies to be delivered IA for maximal local effect. Sprifermin is a recombinant human fibroblast growth factor 18 given IA that promotes chondrocyte growth, and recent two year results from a phase II RCT suggest reduction in cartilage loss with the active therapy, though no benefits above placebo for pain. Phase II data from an RCT of a small molecule Wnt signalling pathway inhibitor (SM04690) given IA has also been reported, with sub-analyses reporting benefits on symptoms and X-ray joint space width. There has recently been increased understanding of the performance metrics of Xray and MRI, with modern supervised machine learning techniques enabling sensitive assessment of OA progression with reduced patient numbers. In a six month phase II dose-ranging study of a novel oral cathepsin-K inhibitor (MIV-711), although the primary pain outcome was not achieved, significant reduction in MRI bone shape change (the most sensitive measure of OA progression and a predictor of joint replacement) was demonstrated with both doses of active agent. Disclosures: P.C. consultancies; Abbvie, BMS, Centrexion, Flexion, GSK, Medivir, Novartis, Pfizer. Member of speakers' bureau; Abbvie, BMS, Samumed.
I079 THE CURRENT EVIDENCE FOR NURSE-LED CARE IN PEOPLE WITH INFLAMMATORY ARTHRITIS
Mwidimi Ndosi 1 1 Rheumatology, UWE Bristol, Bristol, UNITED KINGDOM Inflammatory arthritis includes rheumatoid arthritis (RA), psoriatic arthritis, reactive arthritis, and ankylosing spondylitis, RA being the most common type. IA negatively affects patients' health-related quality-of-life including physical and mental domains. Early treatment with the target of a sustained remission or state of low disease activity leads to good outcomes and reduction of the risk for comorbidity and mortality. Rheumatology nurse-led care is established in the UK. Rheumatology nurse specialists are engaged in disease monitoring, recommending changes to therapy, monitoring therapy, patient education and providing psychosocial support to patients with IA. This model of care has been shown to be effective, safe and acceptable to patients. Over the last six years, new evidence has emerged supporting the effectiveness of nurse-led care in monitoring and managing disease activity, assessing and managing comorbidities and thus improving the long-term outcomes for people with RA. Also, innovative ways of delivering nurse-led care are developing. This presentation will focus on the current evidence for rheumatology nurse-led care, highlight the gaps in the evidence and suggest ways in which best practice could be implemented and extended to other types of IA. Disclosures: M.N. grants/research support; Co-applicant on a research grant from Bristol Myers Squibb. The awarded research is not related to this presentation.
I080 RECRUITMENT, FOLLOW-UP AND ENSURING GOOD QUALITY DATA IN CLINICAL RESEARCH
Zoe Plummer 1 1 Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UNITED KINGDOM Clinical research and clinical trials are now an accepted and expected part of the work carried out by the NHS. Over 90% of patients think it is important that research is carried out and that they should be offered new treatments by their healthcare professionals. For a number of years the National Institute for Health Research has used metrics to measure the efficiency of research initiation and delivery. These continue to provide an invaluable insight into recurring issues however, many studies still fail to recruit to time and target. For those who celebrate a successful recruitment phase, the relief is short lived as the focus then turns to minimising attrition and ensuring the collection of high quality data. This aim of this presentation is to give useful, practical advice for implementing a number of proven strategies throughout the research lifecycle. These strategies will help ensure successful recruitment and follow-up phases and good quality data. Disclosures: The author has declared no conflicts of interest.
I081 THE EFFECTIVENESS OF PRO-BASED TELE-HEALTH FOLLOW UP IN CONTROLLING DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS
Annette Thurah 1 1 Department of Clinical Medicine/Rheumatology, Aarhus University Hospital, Aarhus, DENMARK Objective: To test the effect of patient-reported outcome (PRO) based tele-health follow-up for tight control of disease activity in patients with rheumatoid arthritis (RA), and the differences between tele-health follow-up performed by rheumatologists or rheumatology nurses. Methods: A total of 294 patients were randomised (1:1:1) to either PRO-based tele-health follow-up carried out by a nurse (PRO-TN) or a rheumatologist (PRO-TR), or conventional out-patient follow-up by physicians. The primary outcome was change in DAS28 after week 52. Secondary outcomes were: physical function, quality of life and selfefficacy. The non-inferiority margin was a DAS28 change of 0.6. Mean 
